LAVAL, QC / ACCESSWIRE / July 13, 2023 / Bausch Health Companies Inc. (NYSE/TSX:BHC) will release its second-quarter financial results on Thursday, Aug. 3, 2023. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EDT to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.
Conference Call Details
|
Date:
|
Thursday, Aug. 3, 2023
|
|
Time:
|
8:00 a.m. U.S. EDT
|
|
Webcast:
|
A replay of the conference call will be available on the investor relations website.
To participate in the live Q&A session, please register using this link to receive a PIN, which will be sent an hour before the conference call.
About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX:BHC) is a global diversified pharmaceutical company whose mission is to improve people’s lives with our health care products. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. With our leading durable brands, we are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn.
Investor Contact:
Mark Maico
ir@bauschhealth.com
(877) 281-6642 (toll-free)
(908) 541-2102
Media Contact:
Kevin Wiggins
corporate.communications@bauschhealth.com
(908) 541-3785
SOURCE: Bausch Health Companies Inc.
View source version on accesswire.com:
https://www.accesswire.com/767436/Bausch-Health-to-Announce-Second-Quarter-2023-Results-on-Aug-3
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…